South Korean Biohealth Startup SCBIO has raised USD 10.2 million(KRW 14 billion) in its Series B funding round. Investors included Union Investment Partners, Hyundai Technology Investment, Pioneer Investments, SL Investment, Kolon Investment, KDB Infrastructure Asset Management, Enlight Ventures, and Xquared, with iM Investment Partners and Korea Investment Accelerator providing follow-on commitments.

With this round, SCBIO’s cumulative funding has reached USD 22.6 million(KRW 31 billion), including  USD 4.4 million(KRW 6 billion) in pre-Series A and USD 8.0 million(KRW 11 billion) in Series A financing. The company plans to use the new capital to advance clinical trials for its lead pipeline, continue R&D for subsequent drug candidates, and accelerate global licensing negotiations as part of its growth strategy.

SCBIO’s Sirt6-targeting anticancer drug SCB002 has demonstrated strong efficacy and safety in multiple animal models, completed preclinical studies, and has submitted an IND application for Phase I trials in Korea. Its immuno-oncology candidate SCB001 is expected to file a domestic IND application next year.

Additionally, SCBIO is developing SCB003 and SCB010 using its proprietary next-generation antibody-drug conjugate (ADC) platform, designed to overcome the high toxicity and side effects of conventional ADCs. These candidates have also shown robust efficacy and safety in preclinical models, further diversifying the company’s pipeline and enhancing its competitiveness as a drug developer.

Both SCB002 and SCB001 were selected by the Korea Drug Development Fund (KDDF) as part of its “Drug R&D Ecosystem Development” projects in 2023 and 2024, respectively.

SCBIO’s R&D capabilities are underpinned by extensive infrastructure, including centers for synthetic chemistry, pharmacology and efficacy evaluation, experimental animals, pharmacokinetics, and toxicity and safety assessment. The company employs over 30 professionals, including executives and staff with extensive experience in new drug development and the pharmaceutical industry.

Park Joo-yeon, Senior Executive at Union Investment Partners, who led the round, stated “SCBIO is developing high-potential drug targets using its established research facilities, backed by outstanding talent capable of commercialization. Our long-term due diligence built strong trust in the company, leading to this investment.”

Chang-hoon Lee, CEO of SCBIO, added “This successful round reflects both market confidence and our technological strength. With the newly secured funds, we will focus fully on clinical development and business expansion.”